Skip to main content
. Author manuscript; available in PMC: 2014 Sep 15.
Published in final edited form as: Clin Cancer Res. 2013 Jun 26;19(18):5127–5135. doi: 10.1158/1078-0432.CCR-12-3127

Figure 3.

Figure 3

Immunohistochemical stains positive of the DTF fibroblast core protein markers, SPARC and CSPG2, in colon cancers (Fig 3A and Fig 3B) and ovarian cancers (Fig 3D and Fig 3E). Patients with co-expressed SPARC and CSPG2 had worse survival in both colon cancers (Fig 3C) and ovarian cancers (Fig 3F).